Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2023-10-09 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
This has reference to your email dated October 9, 2023 bearing reference no. L/SURV/ONL/PV/KA/2023-2024/359 on the captioned subject. We wish to inform you that we have no information/ ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to a stock exchange surveillance department regarding an increase in trading volume. It states that the company has no pending announcements that could affect the stock price or volume. The letter is signed by the Company Secretary and references compliance with SEBI Listing Obligations. The document is short (1067 characters) and does not contain any financial data, report content, or detailed disclosures. It is a regulatory communication responding to an inquiry rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2023-10-09 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited regarding an inquiry about an increase in trading volume. The company states it has no information or pending announcements that could affect the stock price or volume. The letter references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document is short (1070 characters) and is a regulatory communication responding to a surveillance query, not a financial report or announcement of results. It does not contain financial data, management changes, voting results, or other report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance communication.
2023-10-09 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) providing contact details of Key Managerial Personnel authorized to determine materiality of events as per SEBI Listing Obligations and Disclosure Requirements. It is a regulatory compliance communication rather than a financial report, earnings release, or management discussion. The document is short (1515 characters) and does not contain financial data or report content. It is an announcement related to regulatory disclosure requirements, fitting best under Regulatory Filings (RNS).
2023-10-03 English
We wish to inform you that as required under the Regulation 30(5) of SEBI (LODR), 2015, the contact details of the Key Managerial Personnel authorised jointly and/or severally to determine ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges providing contact details of Key Managerial Personnel authorized to determine materiality of events as per SEBI regulations. It is a regulatory compliance disclosure rather than a financial report, management change announcement, or voting result. The document is short (1515 characters) and does not contain financial data or detailed report content. It fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2023-10-03 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing them that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation to import a new pharmaceutical drug (Palivizumab) for sale or distribution. The letter is an official announcement of regulatory approval related to the company's product but does not contain financial data, earnings, management discussion, or any report content. It is a regulatory announcement informing the market about a significant operational update. The document length is short (2265 characters), and it is clearly an announcement rather than a detailed report or filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-09-30 English
AstraZeneca Pharma India Limited receives permission to Import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) informing about AstraZeneca Pharma India Limited receiving permission from the Central Drugs Standard Control Organisation to import a new pharmaceutical drug (Palivizumab). It is an announcement of a regulatory approval related to product import and launch, not a financial report, earnings release, or management discussion. The document is short (2265 characters) and serves as an official intimation to the exchanges. It does not contain financial data, management changes, voting results, or any report publication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.